X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.115
-0.095 (-2.26%)
At close: Apr 28, 2026, 4:00 PM EDT
4.120
+0.005 (0.12%)
After-hours: Apr 28, 2026, 4:10 PM EDT
X4 Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 35.11 | 2.56 | - | - | - | |
| Revenue Growth (YoY) | 1273.21% | - | - | - | - | |
| Cost of Revenue | 5.76 | 0.8 | - | - | - | |
| Gross Profit | 29.36 | 1.76 | - | - | - | |
| Selling, General & Admin | 38.52 | 61.52 | 35.51 | 27.02 | 24.7 | |
| Research & Development | 70.72 | 81.64 | 72.02 | 61.06 | 50.65 | |
| Operating Expenses | 109.24 | 143.16 | 107.52 | 88.08 | 75.35 | |
| Operating Income | -79.88 | -141.4 | -107.52 | -88.08 | -75.35 | |
| Interest Expense | -8.88 | -8.77 | -5.78 | -3.99 | -3.64 | |
| Interest & Investment Income | 4.58 | 5.77 | 4.58 | 0.22 | 0.01 | |
| Other Non Operating Income (Expenses) | 12.03 | 2.26 | 7.63 | -2.5 | 0.06 | |
| EBT Excluding Unusual Items | -72.16 | -142.14 | -101.09 | -94.35 | -78.92 | |
| Merger & Restructuring Charges | -7 | - | - | - | - | |
| Impairment of Goodwill | - | - | - | - | -9.76 | |
| Gain (Loss) on Sale of Assets | - | 105 | - | 0.51 | - | |
| Pretax Income | -79.16 | -37.14 | -101.09 | -93.84 | -88.68 | |
| Income Tax Expense | 0.04 | 0.31 | 0.08 | 0.03 | 0.02 | |
| Net Income | -79.2 | -37.45 | -101.17 | -93.87 | -88.7 | |
| Preferred Dividends & Other Adjustments | - | - | - | 2.55 | 13.94 | |
| Net Income to Common | -79.2 | -37.45 | -101.17 | -96.41 | -102.64 | |
| Shares Outstanding (Basic) | 42 | 7 | 6 | 2 | 1 | |
| Shares Outstanding (Diluted) | 42 | 7 | 6 | 2 | 1 | |
| Shares Change (YoY) | 531.04% | 13.08% | 179.91% | 146.71% | 28.25% | |
| EPS (Basic) | -1.87 | -5.59 | -17.07 | -45.53 | -119.59 | |
| EPS (Diluted) | -1.87 | -5.59 | -17.07 | -45.53 | -119.59 | |
| Free Cash Flow | -85.62 | -131.23 | -96.57 | -77.21 | -71.52 | |
| Free Cash Flow Per Share | -2.02 | -19.58 | -16.29 | -36.46 | -83.33 | |
| Gross Margin | 83.60% | 68.83% | - | - | - | |
| Operating Margin | -227.50% | -5529.96% | - | - | - | |
| Profit Margin | -225.56% | -1464.61% | - | - | - | |
| Free Cash Flow Margin | -243.84% | -5132.07% | - | - | - | |
| EBITDA | -78.61 | -140.61 | -107.1 | -87.57 | -74.85 | |
| EBITDA Margin | -223.87% | - | - | - | - | |
| D&A For EBITDA | 1.28 | 0.8 | 0.42 | 0.51 | 0.5 | |
| EBIT | -79.88 | -141.4 | -107.52 | -88.08 | -75.35 | |
| EBIT Margin | -227.50% | - | - | - | - | |
| Revenue as Reported | 35.11 | 2.56 | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.